These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 20929964

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group.
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [Abstract] [Full Text] [Related]

  • 3. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
    Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G.
    J Clin Oncol; 2008 Mar 01; 26(7):1051-7. PubMed ID: 18309940
    [Abstract] [Full Text] [Related]

  • 4. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.
    Lancet Oncol; 2014 Apr 01; 15(4):474-82. PubMed ID: 24636210
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
    Lancet Oncol; 2008 Sep 01; 9(9):840-9. PubMed ID: 18718815
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU, ATAC trialists' group.
    J Steroid Biochem Mol Biol; 2003 Sep 01; 86(3-5):399-403. PubMed ID: 14623537
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 12. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y.
    Oncology; 2010 Aug 01; 79(5-6):376-81. PubMed ID: 21430407
    [Abstract] [Full Text] [Related]

  • 13. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
    Doggrell SA.
    Expert Opin Pharmacother; 2008 Jun 01; 9(9):1619-22. PubMed ID: 18518790
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
    Buzdar AU.
    Clin Breast Cancer; 2004 Sep 01; 5 Suppl 1():S6-S12. PubMed ID: 15347433
    [Abstract] [Full Text] [Related]

  • 20. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
    Duffy SR, Distler W, Howell A, Cuzick J, Baum M.
    Am J Obstet Gynecol; 2009 Jan 01; 200(1):80.e1-7. PubMed ID: 19019322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.